Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 89105-94-2
2. Chembl409436
3. Fibrinogen-binding Inhibitor Peptide
4. Dtxsid10433062
5. Hishisleuglyglyalalysglnalaglyaspval
6. Bdbm50034686
7. Mfcd00167528
8. Ncgc00167215-01
Molecular Weight | 1189.3 g/mol |
---|---|
Molecular Formula | C50H80N18O16 |
XLogP3 | -9.7 |
Hydrogen Bond Donor Count | 18 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 39 |
Exact Mass | 1188.59996854 g/mol |
Monoisotopic Mass | 1188.59996854 g/mol |
Topological Polar Surface Area | 547 Ų |
Heavy Atom Count | 84 |
Formal Charge | 0 |
Complexity | 2310 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33983
Submission : 2019-07-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33614
Submission : 2019-05-27
Status : Active
Type : II
Human fibrinogen drug substance
Registration Number : 227MF10083
Registrant's Address : 1-6-1 Okubo, Kita-ku, Kumamoto City, Kumamoto Prefecture
Initial Date of Registration : 2015-03-12
Latest Date of Registration : 2016-03-23
Details:
Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).
Lead Product(s): Fibrinogen
Therapeutic Area: Hematology Brand Name: Fibryga
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2024
Lead Product(s) : Fibrinogen
Therapeutic Area : Hematology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Fibryga® for Fibrinogen Supplementation in Acquired Deficiency
Details : Fibryga is a fibrinogen concentrate which acts as as fibrinogen replacement therapy. It is approved for the treatment of acquired fibrinogen deficiency (AFD).
Brand Name : Fibryga
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 01, 2024
Regulatory Info :
Registration Country : Switzerland
Brand Name : Haemocomplettan P
Dosage Form : Dry Sub
Dosage Strength : 1g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Haemocomplettan P
Dosage Form : Dry Sub
Dosage Strength : 2g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Fibryga
Dosage Form : Trockensub
Dosage Strength : 1g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 5 7.5cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 45.6cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 7.5cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 23cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 2 23cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Switzerland
Brand Name : Haemocomplettan P
Dosage Form : Dry Sub
Dosage Strength : 1g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Haemocomplettan P
Dosage Form : Dry Sub
Dosage Strength : 2g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Fibryga
Dosage Form : Trockensub
Dosage Strength : 1g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 5 7.5cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 45.6cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 7.5cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 1 23cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Fibrinogen, human, Thrombin, human
Brand Name : TachoSil
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Packaging : Boks 2 23cm2
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
15 Feb 2024
// FIERCE PHARMA
https://www.fiercepharma.com/drug-delivery/grifols-readies-us-eu-approval-push-blood-clot-treatment-after-phase-3-success
https://www.ema.europa.eu/documents/procedural-steps-after/raplixa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
10 Oct 2018
// EMA
https://www.ema.europa.eu/documents/public-statement/public-statement-raplixa-withdrawal-marketing-authorisation-european-union_en-0.pdf
https://www.ema.europa.eu/documents/product-information/raplixa-epar-product-information_en.pdf
https://www.pharmacompass.com/pdf/news/instituto-grifols-sa-veraseal-human-fibrinogen-human-thrombin-receives-approval-in-europe-1516426069.pdf
Global Sales Information
Dosage Form : Dry Sub
Dosage Strength : 1g
Price Per Pack (Euro) : 395.51
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Dosage Form : Dry Sub
Dosage Strength : 2g
Price Per Pack (Euro) : 791.02
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Dosage Form : Trockensub
Dosage Strength : 1g
Price Per Pack (Euro) : 441.12
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 248.11
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 214.24
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 49.62
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 170.44
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Corza Medical GmbH
Dosage Form : Registration for the future
Dosage Strength : 5.5 mg/cm2/2 IE/cm2
Price Per Pack (Euro) : 249.29
Published in :
Country : Norway
RX/OTC/DISCN :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Reply
21 Jun 2021
ABOUT THIS PAGE
A Fibrinogen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fibrinogen, including repackagers and relabelers. The FDA regulates Fibrinogen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fibrinogen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fibrinogen supplier is an individual or a company that provides Fibrinogen active pharmaceutical ingredient (API) or Fibrinogen finished formulations upon request. The Fibrinogen suppliers may include Fibrinogen API manufacturers, exporters, distributors and traders.
click here to find a list of Fibrinogen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fibrinogen DMF (Drug Master File) is a document detailing the whole manufacturing process of Fibrinogen active pharmaceutical ingredient (API) in detail. Different forms of Fibrinogen DMFs exist exist since differing nations have different regulations, such as Fibrinogen USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fibrinogen DMF submitted to regulatory agencies in the US is known as a USDMF. Fibrinogen USDMF includes data on Fibrinogen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fibrinogen USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fibrinogen suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fibrinogen Drug Master File in Japan (Fibrinogen JDMF) empowers Fibrinogen API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fibrinogen JDMF during the approval evaluation for pharmaceutical products. At the time of Fibrinogen JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fibrinogen suppliers with JDMF on PharmaCompass.
Fibrinogen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fibrinogen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fibrinogen GMP manufacturer or Fibrinogen GMP API supplier for your needs.
A Fibrinogen CoA (Certificate of Analysis) is a formal document that attests to Fibrinogen's compliance with Fibrinogen specifications and serves as a tool for batch-level quality control.
Fibrinogen CoA mostly includes findings from lab analyses of a specific batch. For each Fibrinogen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fibrinogen may be tested according to a variety of international standards, such as European Pharmacopoeia (Fibrinogen EP), Fibrinogen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fibrinogen USP).
LOOKING FOR A SUPPLIER?